Pocenbrodib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of the bromodomain of the histone acetyltransferase (HAT) paralogs, CREB binding protein (CBP) and p300 (E1A-associated protein p300; p300 HAT), with potential antineoplastic activity. Upon oral administration, pocenbrodib targets and binds to the bromodomain of CBP and p300. This disrupts the acetylation of histones and other proteins and prevents the co-activation of the androgen receptor (AR) including AR-v7. This may inhibit tumor cell proliferation in AR-positive tumor cells. The HAT paralogs CBP and p300 are key transcriptional co-activators that are essential for a multitude of cellular processes and are implicated in the progression and therapeutic resistance of certain cancers.

**Synonyms:** - CBP/p300 Bromodomain Inhibitor FT-7051 - FT 7051 - FT-7051 - FT7051 - POCENBRODIB - p300/CBP Bromodomain Inhibitor FT-7051